Spravato Treatment in Westbury, NY: A Nasal Spray Built Around the Patients Antidepressants Kept Leaving Behind

Some patients arrive here with a specific version of tired that doesn’t get talked about often. Their depression didn’t ignore their first medication. It just wore it down. The second worked partway. The third stopped feeling like a fresh start and started feeling like paperwork. And by the time they’ve cycled through a handful of options, the illness is still there, quieter than it started but never gone. Findings from Duke University School of Medicine confirm what a lot of these patients already sense: adults whose depression persists across multiple antidepressant trials frequently need an intervention that operates on brain circuitry those medications don’t reach.

Spravato treatment in Westbury exists specifically for that group. Our board-certified team at Anxiety & Depression Psychiatry delivers this FDA-approved nasal spray from both nearby Nassau County offices, and Westbury patients who want to compare against intravenous options can review our ketamine therapy service in Westbury in parallel. If you want a broader look at how public behavioral health services are structured across the region, the New York State Office of Addiction Services and Supports publishes accessible resources for adults navigating co-occurring mental health and substance use concerns.

Our practice runs psychiatric care first. Spravato treatment in Westbury, NY sits inside that larger clinical framework rather than functioning as a standalone product.

Spravato is the brand name for esketamine, a psychiatric medication that gained FDA approval in March 2019 as the first nasal spray created specifically for adults living with treatment-resistant depression. A follow-up approval in 2020 expanded its use to adults with major depressive disorder who are also experiencing active suicidal thoughts.

The clinical distinction that matters here is what Spravato acts on. Most antidepressants target the monoamine system — serotonin, norepinephrine, dopamine — and the mood improvement they produce is downstream of receptor adjustments that unfold over several weeks. Spravato works through a separate route entirely. It targets NMDA receptors within the glutamate network, triggering a fast rise in neuroplasticity, the underlying process the brain relies on to build new circuits and route around damaged ones.

The clearest way to picture it: an oral antidepressant is like sending a slow-moving signal down a saturated cable, waiting for the message to arrive at the other end. Spravato installs a shorter connection. Patients pursuing a Spravato treatment clinic in Westbury often begin to feel the difference within the first few days rather than needing to hold out for two months.

The delivery mechanism itself removes several of the barriers that keep patients from trying interventional care in the first place. No injection. No infusion. No new pill to add to a routine that already feels overloaded.

The FDA didn’t grant either of Spravato’s approvals lightly. The regulatory pathway required a series of large randomized trials in which the medication had to outperform placebo in patients whose depression had already failed at least two prior antidepressants. Few psychiatric medications reach approval under those conditions.

TRANSFORM-2 stood out. Patients starting Spravato alongside a newly initiated oral antidepressant improved substantially more than those started on the same oral antidepressant with placebo nasal spray, and the difference held up when measured at multiple time points. Response often appeared within the opening 24 hours — a timeline no oral antidepressant class approaches.

SUSTAIN-1, published in JAMA Psychiatry, addressed the follow-up question: does the improvement hold? The answer was clear. Patients who stopped Spravato relapsed at rates far higher than those who stayed on maintenance dosing. That data now drives how modern Spravato programs are structured over time.

A few takeaways worth carrying into your consultation:

• New synaptic connections form quickly in mood-regulating regions after dosing
• Response frequently begins within hours, not the weeks required by oral antidepressants
• The medication supports recovery of neural pathways worn down by prolonged illness
• Maintenance dosing is what protects against relapse in the months after induction

For a plain-language patient overview, the University of Michigan Depression Center offers educational material on rapid-acting antidepressants and where they fit in the modern treatment landscape.

Because Spravato holds FDA approval for a narrowly defined set of psychiatric indications, both its safety oversight and its insurance coverage tend to be more predictable than off-label alternatives. Our clinical use follows those indications closely:

Patients whose primary concern falls outside these indications — including PTSD, anxiety disorders, OCD, and bipolar depression — often benefit more from IV ketamine, which our practice provides as well. Your evaluation will clarify which treatment path aligns better with your specific case.

We’ve designed Spravato treatment in Westbury, NY to feel structured from the first phone call through long-term maintenance. You should always know what’s next.

You’ve already shown a level of persistence most people don’t have to sustain — medication after medication, dose adjustment after dose adjustment, month after month of holding out for a response that never quite arrived. There’s now an FDA-approved treatment that operates on a completely separate biological system, delivers through a simple nasal spray, and is covered by most commercial insurance plans.

Spravato treatment in Westbury, NY may be the option that finally makes the difference. Our board-certified team will help you determine whether this fits your case and walk you through every step of what treatment actually looks like.

Call (646) 830-0131 to schedule a consultation. We’ll answer your questions honestly and lay out your options clearly. No pressure, and everything you share stays confidential.

The next treatment doesn’t have to look like the last five.

Monday – Friday, 8am – 5pm Board-certified psychiatrists • Insurance coverage available • Two Long Island locations